+1 (502) 904-2126   One Westbrook Corporate Center, Suite 300, Westchester, IL 60154, USA   Site Map
ISSN: 2574 -1241

Impact Factor : 0.548

  Submit Manuscript

EditorialOpen Access

Pd-1/Pd-L Pathway: Its Preclinical Rationale and Clinical Application in Lymphoid Neoplasm’s

Nahla A M Hamed*

DOI: 10.26717/BJSTR.2017.01.000159

  • Author Information Open or Close
    • Faculty of Medicine, Alexandria University, Egypt

    *Corresponding author: Nahla A M Hamed, Faculty of Medicine, Alexandria University, Egypt

Received: June 26, 2017   Published: June 29, 2017

To view the Full Article   Peer-reviewed Article PDF


The PD-1/PD-L1 pathway plays an important role in mediating immune tolerance in physiological stateand is an important mechanism by which malignancies can evade the host immune response. PD-1 inhibitors may be particularly attractive for hematologic malignancies because the activation of adoptive immunity has been proven effective in the form of allogeneic stem cell transplantation. Clinical trials of anti-PD-1 monoclonal antibodies have demonstrated promising results in lymphoma patients with advanced disease.

Abbreviations: PD-1: Programmed Death-1; FL: Follicular Lymphoma; CHL: Classical Hodgkin Lymphoma; BL: Burkitt Lymphoma; DLBCL: Diffuse Large B-Cell Lymphoma; PI3K: Phosphatidylinositol-4,5-Bisphosphate 3-Kinase; PTEN: Phosphatase And Tensin Homologue; PCNSL: Primary Central Nervous System Lymphoma; PTL: Primary Testicular Lymphoma; HRS: Hodgkin And Reed-Sternberg; TCL: T-Cell Lymphomas

Introduction | Conclusion | References |